Association of fibrotic markers with diastolic function after STEMI

Area of Science:

• Cardiology
• Biomarkers
• Myocardial Infarction

Background:

• Cardiac fibrosis is linked to galectin-3 and soluble suppression of tumorigenicity-2 (sST2).
• Diastolic dysfunction and long-term outcomes are critical post-ST-elevated myocardial infarction (STEMI).

Purpose of the Study:

• To evaluate the prognostic value of galectin-3 and sST2 for diastolic dysfunction and survival in STEMI patients.
• To determine the association between fibrotic markers and cardiac outcomes following myocardial infarction.

Main Methods:

• Analysis of 236 non-diabetic STEMI patients from the GIPS-III cohort.
• Echocardiographic studies and plasma measurements at hospitalization and 4-month follow-up.
• Adjusted logistic mixed effects modeling and 5-year survival analysis.

Main Results:

• No association was found between galectin-3 or sST2 levels and the development of diastolic dysfunction over time.
• No significant differences in 5-year survival outcomes were observed between patients with normal versus abnormal galectin-3 or sST2 levels.
• Galectin-3 and sST2 were not predictive of diastolic dysfunction or survival in this STEMI cohort.

Conclusions:

• Galectin-3 and sST2 are not associated with the development of diastolic dysfunction in non-diabetic STEMI patients.
• These fibrotic markers do not appear to predict long-term survival outcomes in this specific patient population.
• Further research may be needed to clarify the role of these markers in different patient subgroups or cardiac conditions.